Pig-to-baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade

Xenotransplantation

Volumn 21, Issue 3, 2014, Pages 274-286

  Lamattina, John C ^a   Burdorf, Lars ^a   Zhang, Tianshu ^a   Rybak, Elana ^a   Cheng, Xiangfei ^a   Munivenkatappa, Raghava ^a   Salles, Isabelle I ^b   Broos, Katleen ^b   Sievert, Evelyn ^a   McCormick, Brian ^a   Decarlo, Marc ^a   Ayares, David ^c   Deckmyn, Hans ^b   Azimzadeh, Agnes M ^a   Pierson III, Richard N ^a   Barth, Rolf N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c REVIVICOR INC   (United States)

Author keywords

ex vivo perfusion; liver transplantation; xenotransplantation

Indexed keywords

ALPHA GLYCOPROTEIN IB ANTIBODY; ANTIBODY; DESMOPRESSIN; GALACTOSYLTRANSFERASE; GLYCOPROTEIN IB; HEPARIN; MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ALPHA-1,3-GALACTOSYLTRANSFERASE 1, PORCINE; BIOLOGICAL MARKER; CD46 PROTEIN, HUMAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; THROMBIN RECEPTOR;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; BILE; BLOOD CLOTTING DISORDER; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSS CIRCULATION; DNA MODIFICATION; FEMALE; GENE INACTIVATION; LIVER PERFUSION; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWINE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VASCULAR RESISTANCE; XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; EVALUATION STUDY; EXTRACORPOREAL CIRCULATION; GENETICS; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; METABOLISM; POSTOPERATIVE COMPLICATIONS; PROCEDURES; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD46; BIOLOGICAL MARKERS; EXTRACORPOREAL CIRCULATION; GALACTOSYLTRANSFERASES; GENE KNOCKOUT TECHNIQUES; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PAPIO; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; POSTOPERATIVE COMPLICATIONS; SWINE; THROMBOCYTOPENIA; TRANSPLANTATION, HETEROLOGOUS; VON WILLEBRAND FACTOR;

EID: 84901946767     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12093     Document Type: Article

References (28)

1. Ekser B, Long C, Echeverri GJ, et al. Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transplant 2010; 10: 273-285.
2. Pascher A, Sauer IM, Hammer C, Gerlach JC, Neuhaus P,. Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation 2002; 9: 309-324.
3. Schulte am Esch J II, Cruz MA, Siegel JB, Anrather J, Robson SC,. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood 1997; 90: 4425-4437.
4. Robson SC, Cooper DK, d'Apice AJ,. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7: 166-176.
5. Cowan PJ, Roussel JC, d'Apice AJ,. The vascular and coagulation issues in xenotransplantation. Curr Opin Organ Transplant 2009; 14: 161-167.
6. Schulte Am Esch J II, Robson SC, Knoefel WT, Hosch SB, Rogiers X,. O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 2005; 12: 30-37.
7. Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66: 244-251.
8. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888-896.
9. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8: 1101-1112.
10. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749-758.
11. Lee KF, Salvaris EJ, Roussel JC, et al. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008; 15: 191-197.
12. Matsushita T, Amiot B, Hardin J, Platt JL, Nyberg SL,. Membrane pore size impacts performance of a xenogeneic bioartificial liver. Transplantation 2003; 76: 1299-1305.
13. Nyberg SL, Yagi T, Matsushita T, et al. Membrane barrier of a porcine hepatocyte bioartificial liver. Liver Transpl 2003; 9: 298-305.
14. Waldman JP, Vogel T, Burlak C, et al. Blocking porcine sialoadhesin improves extracorporeal porcine liver xenoperfusion with human blood. Xenotransplantation 2013; 20: 239-251.
15. Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation 2003; 10: 460-469.
16. Chari RS, Collins BH, Magee JC, et al. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med 1994; 331: 234-237.
17. Horslen SP, Hammel JM, Fristoe LW, et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000; 70: 1472-1478.
18. Nishitai R, Ikai I, Terajima H, et al. Influence of extracorporeal porcine liver perfusion on nonhuman primates: minimizing hemolysis improves subsequent survival. Liver Transpl 2001; 7: 615-622.
19. Cauwenberghs N, Meiring M, Vauterin S, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-1353.
20. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N,. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002; 22: 323-328.
21. Fontayne A, Meiring M, Lamprecht S, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008; 100: 670-677.
22. Nguyen BN, Azimzadeh AM, Zhang T, et al. Life-supporting function of genetically modified swine lungs in baboons. J Thorac Cardiovasc Surg 2007; 133: 1354-1363.
23. Matsushita T, Ikai I, Nishitai R, et al. Suppressed complement activation in human decay accelerating factor transgenic porcine liver cross-circulated with nonhuman primates. Transplantation 2003; 75: 1807-1812.
24. Terajima H, Shirakata Y, Yagi T, et al. Successful long-term xenoperfusion of the pig liver: continuous administration of prostaglandin E1 and insulin. Transplantation 1997; 63: 507-512.
25. Uesugi T, Ikai I, Yagi T, et al. Evaluation of ammonia and lidocaine clearance, and galactose elimination capacity of xenoperfused pig livers using a pharmacokinetic analysis. Transplantation 1999; 68: 209-214.
26. Ekser B, Echeverri GJ, Hassett AC, et al. Hepatic function after genetically engineered pig liver transplantation in baboons. Transplantation 2010; 90: 483-493.
27. Kim YT, Lee HJ, Lee SW, et al. Pre-treatment of porcine pulmonary xenograft with desmopressin: a novel strategy to attenuate platelet activation and systemic intravascular coagulation in an ex-vivo model of swine-to-human pulmonary xenotransplantation. Xenotransplantation 2008; 15: 27-35.
28. Ekser B, Gridelli B, Cooper DK,. Porcine alanine transaminase after liver allo-and xenotransplantation. Xenotransplantation 2012; 19: 52-55.